Long-Term Durability and Clinical Stability of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A 54-Month Synthesis
Posted inCardiology Clinical Updates Diabetes & Endocrinology news

Long-Term Durability and Clinical Stability of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A 54-Month Synthesis

This review synthesizes the 54-month results of the ATTRibute-CM open-label extension, demonstrating that early and continuous acoramidis treatment provides sustained reductions in mortality and cardiovascular hospitalizations while maintaining functional capacity and biomarker stability in ATTR-CM patients.
Long-Term Academic Performance Following Prenatal Opioid Analgesic Exposure: A Population-Based Risk Assessment
Posted inClinical Updates news

Long-Term Academic Performance Following Prenatal Opioid Analgesic Exposure: A Population-Based Risk Assessment

This review analyzes the association between in utero prescription opioid exposure and third-grade academic outcomes, highlighting a distinct risk signal for tramadol compared to codeine and oxycodone **Outlining Key Sections** I'm now structuring the "Clinical Updates" piece. I've drafted the background, focusing on the opioid epidemic and the need for pain management during pregnancy. I'm building out subsections for the Varney et al. study, emphasizing the reading/numeracy score data. The draft of the "Key Content" is coming together, and I will be working on addressing potential confounders to provide a comprehensive analysis. I am planning the structure of the "Expert Commentary" section. .
Optimizing Influenza Protection in the Aging Diabetic Population: Evidence from the DANFLU-2 High-Dose Vaccine Trial
Posted inClinical Updates Diabetes & Endocrinology news Respiratory

Optimizing Influenza Protection in the Aging Diabetic Population: Evidence from the DANFLU-2 High-Dose Vaccine Trial

This secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines provide superior protection against cardiorespiratory and cardiovascular hospitalizations in older adults with diabetes, particularly those with a disease duration exceeding five years.
Post-Transplant Cyclophosphamide as a Potent Strategy for Bronchiolitis Obliterans Syndrome Prevention: A Comprehensive Clinical Synthesis
Posted inClinical Updates news Respiratory Transplantation

Post-Transplant Cyclophosphamide as a Potent Strategy for Bronchiolitis Obliterans Syndrome Prevention: A Comprehensive Clinical Synthesis

This review evaluates the role of post-transplant cyclophosphamide (PTCy) in reducing the risk of bronchiolitis obliterans syndrome (BOS), highlighting recent multicenter data that demonstrates a 75% risk reduction mediated by the prevention of chronic graft-versus-host disease.